Search
In recent decades, field and semi-field studies of malaria transmission have gathered geographic-specific information about mosquito ecology, behaviour and their sensitivity to interventions. Mathematical models of malaria transmission can incorporate such data to infer the likely impact of vector control interventions and hence guide malaria control strategies in various geographies.
The clinical development of novel vaccines, injectable therapeutics, and oral chemoprevention drugs has the potential to deliver significant advancements in the prevention of Plasmodium falciparum malaria. These innovations could support regions in accelerating malaria control, transforming existing intervention packages by supplementing interventions with imperfect effectiveness or offering an entirely new tool.
Melissa Penny PhD, PD, BSc (Hons) Professor Fiona Stanley Chair in Child Health Research melissa.penny@thekids.org.au Professor Fiona Stanley Chair
Julian is the Program Manager for the Global Disease Modelling team at The Kids Research Institute Australia.
Epke is a veterinarian that specializes in infectious disease control, and holds a PhD in human neglected tropical disease (NTD) control and elimination.
The Global Disease Modelling group informs development and implementation of drugs, medical treatments and non-medical interventions to effectively tackle disease. They build mathematical models of diseases, designed to take into account the complex constellation of interactions between pathogens, humans, diseases, the environment and entire healthcare systems.
Immunomodulatory proteins in human milk (HM) can shape infant immune development. However, strategies to modulate their levels are currently unknown. This study investigated whether maternal prebiotic supplementation alters the levels of immunomodulatory proteins in HM.
When models are used to inform decision-making, both their strengths and limitations must be considered. Using malaria as an example, we explain how and why models are limited and offer guidance for ensuring a model is well-suited for its intended purpose.
In 2022, the World Health Organization extended their guidelines for perennial malaria chemoprevention (PMC) from infants to children up to 24 months old. However, evidence for PMC's public health impact is primarily limited to children under 15 months. Further research is needed to assess the public health impact and cost-effectiveness of PMC, and the added benefit of further age-expansion. We integrated an individual-based model of malaria with pharmacological models of drug action to address these questions for PMC and a proposed age-expanded schedule (referred as PMC+, for children 03-36 months).
Malaria is a leading cause of death in school-aged children in sub-Saharan Africa, and non-fatal chronic malaria infections are associated with anaemia, school absence and decreased learning, preventing children from reaching their full potential. Malaria chemoprevention has led to substantial reductions in malaria in younger children in sub-Saharan Africa.